GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioSpecifics Technologies Corp (NAS:BSTC) » Definitions » Cyclically Adjusted PS Ratio

BioSpecifics Technologies (BioSpecifics Technologies) Cyclically Adjusted PS Ratio : (As of May. 05, 2024)


View and export this data going back to 1991. Start your Free Trial

What is BioSpecifics Technologies Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


BioSpecifics Technologies Cyclically Adjusted PS Ratio Historical Data

The historical data trend for BioSpecifics Technologies's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioSpecifics Technologies Cyclically Adjusted PS Ratio Chart

BioSpecifics Technologies Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioSpecifics Technologies Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioSpecifics Technologies's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, BioSpecifics Technologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioSpecifics Technologies's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioSpecifics Technologies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BioSpecifics Technologies's Cyclically Adjusted PS Ratio falls into.



BioSpecifics Technologies Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

BioSpecifics Technologies's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2020 is calculated as:

For example, BioSpecifics Technologies's adjusted Revenue per Share data for the three months ended in Sep. 2020 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2020 (Change)*Current CPI (Sep. 2020)
=1.528/109.8149*109.8149
=1.528

Current CPI (Sep. 2020) = 109.8149.

BioSpecifics Technologies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201012 0.182 92.474 0.216
201103 0.258 94.283 0.301
201106 0.698 95.235 0.805
201109 0.271 95.727 0.311
201112 0.407 95.213 0.469
201203 0.371 96.783 0.421
201206 0.373 96.819 0.423
201209 0.352 97.633 0.396
201212 0.503 96.871 0.570
201303 0.572 98.209 0.640
201306 0.469 98.518 0.523
201309 0.454 98.790 0.505
201312 0.581 98.326 0.649
201403 0.393 99.695 0.433
201406 0.377 100.560 0.412
201409 0.565 100.428 0.618
201412 0.645 99.070 0.715
201503 0.777 99.621 0.857
201506 0.652 100.684 0.711
201509 0.860 100.392 0.941
201512 0.839 99.792 0.923
201603 0.903 100.470 0.987
201606 0.850 101.688 0.918
201609 0.945 101.861 1.019
201612 0.907 101.863 0.978
201703 1.049 102.862 1.120
201706 0.892 103.349 0.948
201709 0.891 104.136 0.940
201712 0.917 104.011 0.968
201803 0.971 105.290 1.013
201806 1.073 106.317 1.108
201809 1.110 106.507 1.144
201812 1.340 105.998 1.388
201903 1.108 107.251 1.134
201906 1.204 108.070 1.223
201909 1.283 108.329 1.301
201912 1.598 108.420 1.619
202003 1.313 108.902 1.324
202006 0.530 108.767 0.535
202009 1.528 109.815 1.528

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BioSpecifics Technologies  (NAS:BSTC) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


BioSpecifics Technologies Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of BioSpecifics Technologies's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BioSpecifics Technologies (BioSpecifics Technologies) Business Description

Traded in Other Exchanges
N/A
Address
35 Wilbur Street, Lynbrook, NY, USA, 11563
BioSpecifics Technologies Corp is a biopharmaceutical company that specializes in collagenase for multiple indications. Injectable collagenase is marketed in various geographic regions, including the U.S., the EU, and Australia, under the Xiaflex name. The targeted diseases are Dupuytren's contracture and Peyronie's disease. The company is also researching the development of Xiaflex as a solution for new potential indications, such as uterine fibroids, adhesive capsulitis, cellulite, lateral hip fat, plantar fibromatosis, and human and canine lipomas.
Executives
Paul Gitman director 167 EXECUTIVE DRIVE MANHASSET HILLS NY 11040
Michael Schamroth director 191 MEADOWVIEW AVENUE HEWLETT NY 11557
Toby Wegman director, 10 percent owner 4092 BOCAIRE BLVD. BOCA RATON FL 33487
Mark N Wegman director 43 OVERLOOK ROAD OSSINING NY 10562
Jennifer M Chao director 7 PURITAN WOODS ROAD, RYE NY 10580
Joseph Truitt director, officer: Chief Executive Officer C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Michael A. Sherman director 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Fishman Corey N. director DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Patrick Hutchison officer: Chief Financial Officer C/O BIOSPECIFICS TECHNOLOGIES CORP 2 RIGHTER PARKWAY SUITE 200 WILMINGTON DE 19803
J Kevin Buchi director, officer: Chief Executive Officer 41 MOORES ROAD, FRAZER PA 19355
Patrick M Caldwell officer: Principal Financial Officer C/O PROTINE DESIGN LAB 532 BELLA CALAIS WAY SAN JOSE CA 94138
Jyrki Mattila director AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Ronald Edward Law officer: SVP Business Development 23733 N. LOOKOUT PT. ROAD, LAKE BARRINGTON IL 60010
Thomas Wegman director, 10 percent owner, officer: President 1764 BRIAR PLACE MERRICK NY 11566
Estate Of Edwin H. Wegman 10 percent owner 4092 BOCAIRE BLVD. BOCA RATON FL 33487

BioSpecifics Technologies (BioSpecifics Technologies) Headlines